Higher Corporation held the '2026 HILO WAVE Grand Symposium (WAVE: UNFOLDED)' in Seoul on June 27. HILO WAVE is built on Dual-HA (DHC, Dual Hyaluronic Acid Compound), combining non-crosslinked high- and low-molecular-weight hyaluronic acid (HA) with minimally crosslinked HA, and has carved out a new category in the skin booster market. The symposium ran across three sessions, from basic mechanisms to clinical application and practice-focused panel discussions. In Sessions 1 and 2, Drs. Doyoung Rhee, Hyojin Roh, Hyoungmoon Kim, Soeun Kim, Gwahnwoo Cheon, and Jinoh Kim, along with Professor Kyunghee Byun, presented on topics ranging from the biological mechanism and physicochemical properties of Dual-HA to clinical use in the under-eye area, along with exploratory observations in pigmentary concerns and hair loss. In Session 3, with Dr. Kooil Seo as chair, a panel of eight physicians — Drs. Dohoon Kim, Jung Min, Moohyun Son, Hyoseung Jang, Arim Min, Hyochul Shin, Hansaem Kim, and Hyunhee Lee — discussed a broad range of topics, from adoption criteria to treatment-area and dosing strategies to managing treatment-related adverse events. Higher Corporation said it will expand HILO WAVE into a Dual-HA platform and announced that it will unveil 'HILO WAVE id,' a Dual-HA skin booster designed for intradermal delivery, on July 13.
#MedicalAestheticNews #HigherCorporation #HILOWAVE #HILOWAVEid
★ Article Link: https://www.medicalaestheticnews.com/news/articleView.html?idxno=20098





Comments
Post a Comment